NEW YORK, May 22, 2012 (GLOBE NEWSWIRE) -- Alliqua, Inc. (OTCBB:ALQA) ("Alliqua" or the "Company"), an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and liver health technologies, today announced the addition of Michael F. Moore, MD, FACCWS, to its Scientific Advisory Board ("SAB"). The SAB will provide scientific perspectives and strategic insight to enable Alliqua to leverage its hydrogel technology platform in the fields of wound care, transdermal drug delivery and other medical related categories.
Dr. Moore is a graduate of Fairfield University and Albany Medical College. He completed his general surgical training and vascular fellowship at the Albany Medical Center Hospitals. Dr. Moore pioneered the treatment of wound care in northeastern Pennsylvania establishing the first wound center in 1997 and has practiced in the region since 1983. Presently as the Medical Director of the Wound Institute and Research Center in Dunmore PA, Dr. Moore is conducting research involving interactive dressings and dietary supplements. In his role as medical consultant for Noble Biomaterials and RJL Systems, he is the principal investigator involving the development of a physiologic electronic garment with the US Air Force and the development of a hemostatic antimicrobial dressing for the US Army. Dr. Moore has been elected to the Board of Directors of the Fellows of the American College of Certified Wound Specialists and the advisory nutrition board for Abbott Laboratories.
"We are privileged to have the opportunity to collaborate closely with Dr. Moore, who is recognized as an expert in the field of wound care. We look forward to employing his expertise to identify new opportunities for our hydrogel technology platform. Dr. Moore has extensive clinical and academic experience that will ensure that Alliqua is going to generate and develop an enhanced high quality pipeline of products," stated Richard Rosenblum, President of Alliqua.
Dr. Moore commented, "Over the past several years, I have had the opportunity to evaluate the Company's SilverSeal® Hydrogel and believe that it is a 'best in class' type product with respect to multiple wound care applications, particularly diabetic ulcers and skin tears. I look forward to advancing the product and the technology platform as I believe it will help make a higher standard of care available to the wound care community."
About Alliqua, Inc.
Alliqua, Inc. (OTCBB:ALQA) ("Alliqua"), is an advanced biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. Through its wholly-owned subsidiary, Alliqua BioMedical, Inc., Alliqua intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform of AquaMed Technologies, Inc. ("AquaMed"), Alliqua's subsidiary.
AquaMed manufactures custom hydrogels used for transdermal drug delivery, wound care, medical diagnostics, and cosmetics. These products use proprietary manufacturing technologies which enable AquaMed to produce what is known in the healthcare industry as high water content, electron beam cross-linked aqueous polymer sheet hydrogels. AquaMed believes that it is one of two manufacturers in the world for these gels. Alliqua's third subsidiary, HepaLife Biosystems, Inc., focuses on the development of a cell-based bioartificial liver system, known as HepaMate™.
Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.
For additional information, please visit www.alliqua.com
To receive future press releases via email, please visit: http://alliqua.com/index.php?page=investor-alerts
The Alliqua, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8820
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the our control that can make such statements untrue, including, but not limited to, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on March 31, 2011 and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.